-10%

Semaglutide 8mg Injection Pen Kit - Image 2

Semaglutide 8mg Injection Pen Kit - Image 3

Semaglutide 8mg Injection Pen Kit - Image 4

Semaglutide 8mg Injection Pen Kit - Image 5

Semaglutide 8mg Injection Pen Kit

Original price was: £150.00.Current price is: £135.00.

Semaglutide 8mg Injection Pen Kit contains semaglutide in a pre-filled injection pen format. The 8mg amount may refer to the total quantity contained in the pen rather than an individual injection dose. Use only according to the authorised product information and instructions from your healthcare professional.

What does the 1mg Kit Contain?

2 × Synedica semaglutide pens (each containing 4mg)
12 × disposable 32g 4mm needles
1 × instruction booklet

Each pen delivers up to 4 full doses of 1mg or smaller increments of 0.25mg, 0.5mg, 0.75mg, or 1mg, depending on your prescribed dosage.

Recommended Dosage Schedule:

Weeks 1–4: 0.25mg once weekly
Weeks 5–8: 0.5mg once weekly
After 8 weeks: Your doctor may increase to 0.75mg or 1mg once weekly

Categories: Weight Loss, Weight Management Tags: GLP-1 Injection, GLP-1 medicine, Pre-filled injection pen, Prescription Medicine UK, semaglutide 8mg, semaglutide injection pen, semaglutide injection UK, semaglutide medicine, semaglutide pen UK, semaglutide prescription, weight management medicine Brand: Ozempic

Description
Reviews (0)

Semaglutide 8mg Injection Pen Kit

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in authorised medicines for specific medical conditions. It is available in pre-filled injection pens and should be used only according to the instructions provided with the specific medicine and the advice of a qualified healthcare professional.

Important information about the 8mg pen

The term “8mg pen” should not automatically be interpreted as an 8mg individual injection dose. For example, the UK Ozempic 2mg/dose pre-filled pen contains 8mg of semaglutide in total and delivers four doses of 2mg. Patients should always check the product name, strength and dosing instructions on their packaging and follow the directions provided by their prescriber.

What is semaglutide?

Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists. These medicines mimic the action of a naturally occurring hormone involved in appetite and blood glucose regulation.

In the UK, different semaglutide medicines have different licensed indications. Ozempic and Rybelsus are licensed for the treatment of type 2 diabetes, while Wegovy is licensed for weight management in eligible patients. Therefore, the brand and authorised indication should always be checked before treatment is started.

The MHRA confirms that GLP-1 medicines are prescription-only medicines in the UK and should only be used when prescribed by an appropriate healthcare professional.

Semaglutide 8mg injection pen information

A pre-filled semaglutide pen is designed to provide measured doses of medicine according to the specific product’s authorised instructions. The amount printed on the pen or packaging can represent the total quantity contained in the device rather than the amount delivered in one injection.

For example, the current UK Ozempic patient information states that an 8mg pre-filled pen contains 8mg of semaglutide in 3mL solution and provides four 2mg doses.

This distinction is important because patients should never calculate or change their dose based solely on the total amount printed on the pen.

Prescription requirements in the UK

Semaglutide GLP-1 medicines are prescription-only medicines. A healthcare professional must assess the patient before a prescription can be issued.

For private treatment, the MHRA states that a consultation with a healthcare professional must take place before a prescription is issued. This allows the prescriber to check whether treatment is appropriate and discuss potential benefits, risks and other relevant medical information.

Patients should not purchase semaglutide from unregulated sellers, social-media accounts, beauty salons or websites that provide the medicine without an appropriate consultation.

For additional information, patients can read the official UK guidance on [GLP-1 medicines for weight loss and diabetes](https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know).

How semaglutide is administered

The exact dose and administration schedule depend on the specific semaglutide product prescribed.

Patients should use the medicine exactly as directed by their healthcare professional and should read the Patient Information Leaflet supplied with the medicine before use.

Do not increase the dose, inject more frequently or change the treatment schedule without speaking to your prescriber.

The current UK Ozempic patient information explains that the 8mg pen is a pre-filled dial-a-dose pen that allows the user to select a 2mg dose. The pen contains four 2mg doses.

For official information, see the [semaglutide product information and Patient Information Leaflet](https://www.medicines.org.uk/emc/product/14975/pil).

Semaglutide and weight management

Some semaglutide medicines are specifically authorised for weight management. Wegovy, for example, is licensed in the UK for eligible patients as part of a treatment plan that includes appropriate dietary and physical-activity measures.

Ozempic, however, is licensed for the treatment of type 2 diabetes rather than weight management. Patients should therefore use the specific semaglutide medicine prescribed for their individual medical indication.

The MHRA advises that GLP-1 medicines should not be used simply for cosmetic or aesthetic weight loss outside their authorised indications.

Patients looking for general information can also visit our [UK weight management information](https://pharmacystoreonline.net/weight-loss/) and explore our [health and weight-management guides](https://pharmacystoreonline.net/blog/) for additional educational information.

Safety information

Like all medicines, semaglutide can cause side effects. Common side effects associated with GLP-1 medicines include gastrointestinal symptoms such as nausea, vomiting, diarrhoea and constipation.

The MHRA has also strengthened warnings concerning acute pancreatitis with GLP-1 medicines. Severe, persistent abdominal pain, particularly pain that may radiate to the back and may occur with nausea or vomiting, requires urgent medical attention.

Very rarely, semaglutide has also been associated with non-arteritic anterior ischemic optic neuropathy (NAION), a serious eye condition that can cause sudden vision loss. Anyone taking semaglutide who experiences sudden or rapidly worsening eyesight should seek urgent medical attention.

Patients should read the complete Patient Information Leaflet for their specific medicine and speak with their doctor, pharmacist or nurse if they have questions about possible side effects.

Pregnancy and breastfeeding

GLP-1 medicines should not be taken during pregnancy or when trying to become pregnant unless specifically directed otherwise by an appropriate healthcare professional.

The MHRA advises that people taking semaglutide should stop the medicine for at least two months before trying to become pregnant.

Patients who become pregnant while taking semaglutide should speak with their healthcare professional promptly.

Storage and handling

Storage requirements vary depending on the specific semaglutide product. Always follow the storage instructions supplied with the medicine and printed in its official Patient Information Leaflet.

For example, the UK Ozempic information states that the pen should be protected from light when it is not being used. Patients should also check that the solution is clear and colourless or almost colourless before use.

Do not use an injectable medicine if the solution does not match the appearance described in the official product information.

Used needles should be disposed of safely in accordance with local guidance and the instructions provided by the pharmacy or healthcare professional.

Semaglutide compared with other GLP-1 medicines

Semaglutide is one of several medicines in the GLP-1 class. Other medicines, including tirzepatide, contain different active ingredients and have different indications, dosing schedules, benefits, contraindications and safety information.

Semaglutide and tirzepatide should not be considered interchangeable products. A healthcare professional should determine which treatment is appropriate based on the patient’s medical history, treatment goals and licensed indications.

Patients should never switch between GLP-1 medicines without first discussing the change with their prescriber.

Buying semaglutide safely in the UK

Prescription medicines should only be obtained through legitimate healthcare and pharmacy channels.

The MHRA warns consumers about falsified and illegally supplied GLP-1 medicines. Legitimate online pharmacies should have appropriate registration and prescribing procedures.

Patients should be particularly cautious of websites or social-media accounts offering semaglutide without a prescription or healthcare consultation.

The official MHRA guidance on [safe access to GLP-1 medicines](https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know) provides further information about legitimate supply and potential risks associated with unregulated products.

Why professional guidance matters

Semaglutide treatment should form part of an appropriate healthcare plan. A prescriber can assess medical history, current medicines, potential interactions, contraindications and the appropriate dose before treatment begins.

Patients should not rely on online dosage calculators, social-media recommendations or another person’s treatment plan when deciding how much semaglutide to use.

If you are unsure about the strength of your pen, the correct dose, storage requirements or administration procedure, contact your doctor, pharmacist or nurse before using the medicine.

Conclusion

Semaglutide 8mg Injection Pen Kit refers to a pre-filled pen format containing semaglutide, but the meaning of the 8mg strength must be checked against the specific product. For the UK Ozempic 2mg/dose pen, 8mg represents the total amount contained in the pen and the pen provides four 2mg doses.

Semaglutide medicines are prescription-only in the UK and should be used only under appropriate healthcare-professional supervision.

Always check the exact product, strength and dosing instructions supplied with your medicine. For official information about a particular semaglutide product, consult its current Patient Information Leaflet and speak with your healthcare professional.

• Active ingredient: Semaglutide
• Pre-filled injection pen format
• 8mg total semaglutide content where applicable
• Prescription-only medicine
• Subcutaneous injection
• Requires healthcare-professional assessment
• Follow the supplied Patient Information Leaflet
• Store according to the specific product instructions
• Do not share the injection pen or needles

Frequently Asked Questions About Semaglutide 8mg Injection Pen Kit

What is a Semaglutide 8mg Injection Pen Kit?

A Semaglutide 8mg Injection Pen Kit is a pre-filled injection pen containing semaglutide. The 8mg amount may refer to the total quantity contained in the pen rather than an individual injection dose. Always check the specific product information supplied with your medicine.

Is semaglutide prescription-only in the UK?

Yes. Semaglutide GLP-1 medicines are prescription-only medicines in the UK. Treatment should be prescribed following an appropriate assessment by a qualified healthcare professional.

Does an 8mg semaglutide pen contain an 8mg dose?

Not necessarily. For example, the UK Ozempic 2mg/dose pen contains 8mg of semaglutide in total and delivers four 2mg doses. Always follow the strength and dosing instructions for your specific prescribed product.

Is semaglutide used for weight management?

Some authorised semaglutide medicines are indicated for weight management in eligible patients. The specific indication depends on the product. Speak with a qualified healthcare professional to determine whether a particular semaglutide medicine is appropriate for you.

How is semaglutide administered?

Authorised injectable semaglutide products are administered by subcutaneous injection according to the specific product instructions and the directions provided by the prescribing healthcare professional.

Can I change my semaglutide dose myself?

No. You should not change your semaglutide dose or treatment schedule without first speaking with your prescribing healthcare professional.

Can I share my semaglutide injection pen?

No. Injection pens and needles should never be shared with another person, even if the needle has been changed.

How should a semaglutide pen be stored?

Storage requirements depend on the specific semaglutide product. Always follow the storage instructions provided with your medicine and in the official Patient Information Leaflet.

What should I do if I experience serious side effects?

Seek appropriate medical advice promptly if you experience concerning or severe symptoms. If you have severe persistent abdominal pain or sudden changes in eyesight, seek urgent medical attention.

How can I make sure my semaglutide medicine is genuine?

Prescription medicines should be obtained through legitimate pharmacy and prescribing channels. Avoid unregulated sellers and products supplied without appropriate healthcare assessment.